Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

The extract in Oralair repeatedly exposes the immune system to grass‑pollen proteins under the tongue. This exposure promotes a shift from a Th2‑dominant allergic response toward a regulatory/Th1 response, increasing IgG4 antibodies and decreasing IgE production, which together diminish allergic inflammation and improve tolerance to grass pollen.

The dosing regimen for Oralair is individualized by the prescribing clinician based on the patient’s age, severity of allergy, and response to therapy. The prescriber determines the starting dose, titration schedule, and maintenance dose, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for Oralair in pregnancy and lactation are limited, and the product is not classified for use in these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before starting treatment.

To request Oralair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oralair is a sublingual immunotherapy tablet, offering a non‑injectable alternative to traditional subcutaneous allergy shots. Compared with antihistamines, it targets the underlying immune response rather than just symptom relief, and it provides long‑term tolerance after a course of treatment, whereas antihistamines require continuous use.

Oralair tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Oralair is taken sublingually. The tablet is placed under the tongue and allowed to dissolve completely without swallowing, chewing, or drinking for a few minutes. Patients should avoid eating or drinking for at least 5 minutes after administration to ensure optimal absorption.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema, and severe bronchospasm. Patients should be monitored after the first dose and instructed to seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or any signs of a severe reaction.

Oralair is contraindicated in individuals with a history of severe systemic reactions to grass‑pollen extracts, uncontrolled asthma, or those currently receiving other allergen immunotherapy products. Patients with known hypersensitivity to any component of the tablet should also avoid its use.